Haemotherapy with Fibrinogen for Perioperative Bleeding Prevention—A view on Arterial Thrombogenesis and Myocardial Infarction in the Rat In Vivo

Autor: Ragnar Huhn, Markus W. Hollmann, Vera Welke, Martin Stroethoff, Friederike Behmenburg, Till Hoffmann, Volker Stoldt, André Heinen
Přispěvatelé: ACS - Heart failure & arrhythmias, AII - Inflammatory diseases, Anesthesiology, ACS - Microcirculation
Rok vydání: 2019
Předmět:
Zdroj: Journal of Clinical Medicine, Vol 8, Iss 6, p 880 (2019)
Journal of Clinical Medicine
Volume 8
Issue 6
Journal of clinical medicine, 8(6). Multidisciplinary Digital Publishing Institute (MDPI)
ISSN: 2077-0383
DOI: 10.3390/jcm8060880
Popis: Major blood loss during cardiac surgery is associated with increased morbidity and mortality. Clinical pilot studies indicated that preoperative fibrinogen supplementation reduces postoperative blood loss without increasing thrombotic complications. However, an increase in fibrinogen concentration might rather aggravate pre-existing thrombosis than increase the incidence of thrombotic events. Therefore, we investigated, in the present study, whether fibrinogen supplementation influences (1) arterial thrombus formation, (2) the extent of myocardial infarction and (3) the cardioprotective effect of ischaemic preconditioning. Arterial thrombogenesis of the femoral artery was induced by topic FeCl3 treatment in anaesthetised Wistar rats after pretreatment with 60 mg/kg (Fiblow), 120 mg/kg (Fibhigh) or vehicle (Con). Vessel blood flow was monitored, and time to vessel occlusion was analysed as a marker for arterial thrombogenesis. In addition, regional myocardial I/R injury was induced by temporary left coronary artery occlusion in rats pretreated with or without fibrinogen supplementation. In additional groups, ischaemic preconditioning (IPC) was induced by 3 cycles of 5 min of ischaemia/reperfusion. In all groups, myocardial infarct size was determined by triphenyltetrazoliumchlorid staining. Arterial thrombogenesis was not affected by fibrinogen pretreatment. No differences in time until vessel occlusion between Con, Fiblow and Fibhigh groups were observed. In addition, fibrinogen supplementation in low and high concentrations had no effect on infarct size after regional myocardial ischaemia and reperfusion (Fiblow: 66 ±
10%, Fibhigh: 62 ±
9%
each ns vs. Con). IPC reduced infarct size from 62 ±
14% to 34 ±
12% (p <
0.05 vs. Con). Furthermore, both fibrinogen concentrations did not affect cardioprotection by ischaemic preconditioning (Fiblow + IPC: 34 ±
11%, Fibhigh + IPC: 31 ±
13%
each ns vs. IPC). Haemotherapy with fibrinogen did not affect arterial thrombogenesis, myocardial infarction and the cardioprotective effect of ischaemic preconditioning.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje